Status:
COMPLETED
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Carcinoma, Non-Small Cell Lung
Carcinoma, Small-Cell Lung
Eligibility:
All Genders
18-100 years
Brief Summary
Background: * The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing ...
Detailed Description
Background: * Lung cancer is the leading cause of cancer deaths among men and women worldwide. * Despite modern surgical, radiation, and chemotherapeutic interventions, the prognosis for patients wit...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients 18 years of age and older are eligible.
- Histologic diagnosis of primary lung carcinoma. For non small cell lung cancer, patients can be stage I to IV, and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy). For small cell lung cancer, patients can be limited or extensive stage and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy).
- Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol.
- Patients with a current diagnosis of or a prior history of other cancers may be included onto this protocol.
- Patients may have either normal organ function or impaired organ function.
- EXCLUSION CRITERIA:
- 1\. Children will not be eligible.
Exclusion
Key Trial Info
Start Date :
March 18 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2018
Estimated Enrollment :
546 Patients enrolled
Trial Details
Trial ID
NCT00923884
Start Date
March 18 2009
End Date
April 20 2018
Last Update
October 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892